BOSTON, March 19, 2014 /PRNewswire/ -- PAREXEL
International Corporation (NASDAQ: PRXL), a leading global
biopharmaceutical services provider, today announced the expansion
of its global Clinical Logistics Services (CLS) capabilities. A
new, state-of-the-art distribution center in Singapore and the recent expansion of the
Company's facilities in Billerica,
Mass., will help PAREXEL more effectively manage clients'
global clinical trial supply requirements.
PAREXEL's Clinical Logistics Services provides synchronized
coordination of clinical trial supplies, central lab services, and
ancillary supplies worldwide to ensure safe and timely
distribution. The Company offers risk evaluation and mitigation
planning for in-time-investigational-site supply, as well as
expertise in global import/export compliance. New capabilities
include secondary packaging and labeling services. The facility
expansion builds upon PAREXEL's considerable global clinical
logistics infrastructure in North
America, Latin America,
Europe, Africa and the Asia/Pacific region.
"As clinical trials increase in size and complexity, clients are
challenged to develop and implement strategies that create
consistent sourcing, manufacturing, storage and distribution
processes along the supply chain," said Mark A. Goldberg, President and Chief Operating
Officer, PAREXEL. "Our investments in these important distribution
centers and depots are part of the Company's ongoing efforts to
simplify the clinical trial journey for biopharmaceutical clients
by supporting their growing global supply and logistics needs."
PAREXEL's clinical logistics facilities offer sophisticated
capabilities that include enhanced expiry and update labeling
services. These services eliminate the need to return supplies to
the manufacturing organization, reduce study start-up time and help
ensure timely first-patient-in milestones. Additional capabilities
include a distribution and warehousing infrastructure to manage and
transport clinical trial supplies to locations worldwide, as well
as leading technology systems that track and trace shipments and
manage inventory levels.
"PAREXEL continues to build a global network of storage and
distribution facilities with harmonized configurations that provide
a consistent and reliable flow of materials needed in the clinical
trial process," said Kurt Norris,
Corporate Vice President, Clinical Logistics Services, PAREXEL.
"This reflects our commitment to provide leading-edge management of
clinical trial materials to clients across the globe."
About PAREXEL International
PAREXEL International Corporation is a leading global
biopharmaceutical services organization, providing a broad range of
knowledge-based contract research, consulting, medical
communications, and technology solutions and services to the
worldwide pharmaceutical, biotechnology and medical device
industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, medical
education and reimbursement. PAREXEL Informatics, Inc., a
subsidiary of PAREXEL, provides advanced technology solutions,
including medical imaging, to facilitate the clinical development
process. Headquartered near Boston,
Massachusetts, PAREXEL operates in 76 locations in 50
countries around the world, and has 15,100 employees. For
more information about PAREXEL International visit
www.PAREXEL.com.
PAREXEL and "Your Journey. Our Mission." are trademarks or
registered trademarks of PAREXEL International Corporation or its
affiliates.
This release contains "forward-looking" statements regarding
future results and events, including, without limitation,
statements regarding expected financial results, future growth and
customer demand. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are
also intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of
risks and uncertainties. The Company's actual future results
may differ significantly from the results discussed in the
forward-looking statements contained in this release.
Important factors that might cause such a difference include, but
are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating
improvements resulting from recent and anticipated restructurings;
the loss, modification, or delay of contracts which would, among
other things, adversely impact the Company's recognition of revenue
included in backlog; the Company's dependence on certain industries
and clients; the Company's ability to win new business, manage
growth and costs, and attract and retain employees; the Company's
ability to complete additional acquisitions, and to integrate newly
acquired businesses including the recent acquisitions of LIQUENT,
Inc. and HERON, Inc., or enter into new lines of business; the
impact on the Company's business of government regulation of the
drug, medical device and biotechnology industry;
consolidation within the pharmaceutical industry and competition
within the biopharmaceutical services industry; the potential for
significant liability to clients and third parties; the potential
adverse impact of health care reform; and the effects of exchange
rate fluctuations and other international economic, political, and
other risks. Such factors and others are discussed more
fully in the section entitled "Risk Factors" of the Company's
Quarterly Report on Form 10-Q for the fiscal quarter ended
December 31, 2013 as filed with the
SEC on January 31, 2014, which "Risk
Factors" discussion is incorporated by reference in this press
release. The Company specifically disclaims any obligation to
update these forward-looking statements in the future. These
forward-looking statements should not be relied upon as
representing the Company's estimates or views as of any date
subsequent to the date of this press release.
Contacts:
Diana Martin,
Vice President, Corporate Communications
PAREXEL International
Tel: +1 781-434-5516
Email: Diana.Martin@PAREXEL.com
Matthew Briggs
PAN Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
SOURCE PAREXEL International Corporation